

PRESS RELEASE
05 July 2022 08:30:00 CEST

Stockholm3 study is named the best scientific publication by the European Association of Urology

Associate Professor Tobias Nordström is awarded the European Association of Urology (EAU) "Prostate Cancer Research Award 2022". He receives the award for the study STHLM3-MRI, which shows that Stockholm3, combined with magnetic camera examination (MRI), reduces the number of unnecessary biopsies by 76 percent in a general screening program. A follow-up health economic study also shows that Stockholm3 reduces the number of MRIs by 60 percent over the man's lifetime, which reduces cost and frees up resources.

"Stockholm3 is now available to healthcare providers throughout the EU. Receiving EAU's research award strengthens the interest in Stockholm3 and shows the great value of the test. The fact that Stockholm3 reduces magnetic camera examinations by 60 percent validates that the test is not only better than the standard PSA test, but also that it reduces the costs of care", says David Rosén, CEO of A3P Biomedical.

In 2021, the results of the STHLM3 MRI-study were published in The Lancet Oncology. The Lancet Editorial described the study as "an important step for smarter screening of prostate cancer". The article also won first prize for best oncological abstract at the EAU Congress in 2021. In early 2022, Professor Henrik Grönberg was awarded the "Cancer Researcher of the Year 2022" award by the Cancer Foundation for his world-leading research that enables early detection of prostate cancer. Henrik Grönberg and his team, which includes Tobias Nordström, at Karolinska Institutet have for many years conducted research in the prostate cancer area. This research has, among other things, resulted in Stockholm3, which has been successfully implemented in clinical use since 2017. Now Tobias Nordström also receives EAU's Prostate Cancer Research Award 2022.

Tobias Nordström is a urologist and researcher at Karolinska Institutet. He is one of Sweden's leading experts in prostate cancer. He is clinically active at Danderyd Hospital and the principal (PI) for the STHLM3 MRI study.

Publications

Prostate cancer screening using a combination of risk-prediction, magnetic resonance imaging and targeted prostate biopsies: results from the population-based STHLM3MRI trial. T. Nordström, A. Discacciati, M. Bergman, M. Clements, M. Aly, M. Annerstedt, A. Glaessgen, S. Carlsson, F. Jäderling, H. Grönberg, M. Eklund. The Lancet Oncology, online 12 augusti 2021, doi: 10.1016/ S1470-2045(21) 00348-X.

Cost-effectiveness of Stockholm3 test and magnetic resonance imaging in prostate cancer screening: a microsimulation study. *European Urology*. <https://doi.org/10.1016/j.eururo.2021.12.021>. Hao, Shuang & Heintz, Emelie & Ostensson, Ellinor & Discacciati, Andrea & Jaderling, Fredrik & Gronberg, Henrik & Eklund, Martin & Nordström, Tobias & Clements, Mark. (2021).

For additional information, please contact:

David Rosen, CEO
Telephone: +46 10 1823325
Email: david.rosen@a3p.com

About A3P Biomedical

A3P Biomedical's mission is to improve quality of life of men by radically increasing the precision in prostate cancer diagnostics. The company's lead product is **Stockholm3**, a blood test for early detection of aggressive prostate cancer. Stockholm3 has been developed by scientists at Karolinska Institutet and validated in clinical studies including more than 75,000 men. A total of SEK 750 million has been invested in clinical research, product development and market validation activities of Stockholm3. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit www.a3p.com.

About Stockholm3

Stockholm3 is a blood test that combines protein markers, genetic markers, clinical data, and a proprietary algorithm, to predict the risk of aggressive prostate cancer at an early stage. In clinical practice, Stockholm3 finds 100 percent more aggressive prostate cancers and reduces 50 percent of unnecessary biopsies compared to current practice with PSA (1).

Stockholm3 has been evaluated in clinical studies with more than 75,000 men. Data from the latest pivotal study, a randomized study including 12,750 men, was published in *The Lancet Oncology* in 2021. Multiple studies have been published in high-impact journals, including a previous study with 58,000 men, published in *The Lancet Oncology* in 2015 (1).

Based on robust peer-reviewed clinical data, leading Nordic healthcare providers such as Capio S:t Görans Hospital in Sweden and Stavanger University Hospital in Norway have replaced PSA with Stockholm3. Region Värmland has introduced general screening for prostate cancer with the help of Stockholm3 for men in the age category 50-75. Patients benefit from a more precise test (increasing sensitivity and specificity) and healthcare providers can reduce the direct costs by 17 to 28 percent (1).

(1) Publications, results and clinical validation.

About prostate cancer

Prostate cancer is the second most common male cancer, and the fifth leading cause of cancer related death in men worldwide. According to WHO, 1.4 million men were diagnosed with prostate cancer and 375,000 deaths were reported in 2020. Incidence of prostate cancer is expected to increase by 70 percent until 2040, driven by an aging population.

Image Attachments

[EAU2022 Tobias Nordström](#)

Attachments

[Stockholm3 study is named the best scientific publication by the European Association of Urology](#)